Remedium Lifecare Limited , a pharmaceutical company specializing in Active Pharmaceutical Ingredients (APIs) and intermediates, has announced significant corporate changes through a postal ballot notice. The company is seeking shareholder approval for three key resolutions that could reshape its identity and leadership structure.

Proposed Name Change

The company is proposing to change its name from Remedium Lifecare Limited to Supha Pharmachem Limited. This change, if approved, would mark a new chapter for the company, although there will be no alteration to the company's core business activities. The Registrar of Companies has confirmed the availability of the new name on October 15, 2025.

New Board Appointments

Two significant board appointments are also on the agenda:

Executive Director Appointment

The company is seeking approval for the appointment of Mr. Vignesh Laxman Gawde as an Executive Director/Whole Time Director for a five-year term. Mr. Gawde, who holds an M.Sc. in Physical Chemistry from the Institute of Science, Mumbai University, is currently a Research Associate at Ajanta Pharma Ltd. If approved, he would receive a monthly compensation of Rs. 50,000.00.

Non-Executive Director and Chairman Appointment

The board is also proposing the appointment of Mr. Rambhajan Vishwakarma as a Non-Executive, Non-Independent Director and Chairman of the Board. Mr. Vishwakarma brings over 15 years of experience in banking product sales, including personal loans, mortgage loans, gold loans, and used car loans. He has previously worked as a Relationship Manager with ICICI Bank.

Voting Details

Shareholders eligible to vote on these resolutions must be on the company's register as of October 31, 2025. The e-voting period is scheduled from November 8 to December 7, 2025. Ms. Riddhi Shah has been appointed as the scrutinizer for the postal ballot process.

Financial Implications

While the proposed name change doesn't suggest any new business activities, it's worth noting that Remedium Lifecare trades in APIs and pharmaceutical intermediates in both domestic and international markets. The appointment of Mr. Gawde, with his background in physical chemistry, could potentially strengthen the company's research capabilities.

Shareholders and investors should carefully consider these proposed changes and their potential impact on the company's future direction. It's advisable to review the full postal ballot notice for complete details before making any investment decisions.

Remedium Lifecare Limited has announced significant changes to its board composition and committee structure, as per a recent filing with the BSE. The company's Board of Directors, in a meeting held on October 31, 2025, approved several key appointments and restructuring measures.

New Board Appointments

The company has made two notable appointments to its board:

1. Mr. Rambhajan Vishwakarma (DIN: 11360922) has been appointed as an Additional Director (Non-Executive, Non-Independent) and Chairman of the Board, effective October 31, 2025.
2. Mr. Vignesh Laxman Gawde (DIN: 11360925) has been appointed as an Additional Executive/Whole-time Director for a five-year term, also effective from October 31, 2025.

Both appointments are subject to shareholder approval within three months or at the next General Meeting, whichever is earlier.

Director Profiles

Board Committee Restructuring

The company has reconstituted four key committees:

1. Audit Committee: Now chaired by Mr. Vijay Pal Singh Gulya (Independent Director)
2. Nomination and Remuneration Committee: Chaired by Mrs. Shamim Adil Michal (Independent Director)
3. Stakeholders Relationship Committee: Chaired by Mr. Rambhajan Vishwakarma
4. Risk Management Committee: Chaired by Mrs. Shamim Adil Michal

It's worth noting that the Nomination and Remuneration Committee was dissolved prior to these appointments due to director resignations, which prevented their recommendation for the new appointments.

Postal Ballot and Other Approvals

The board has approved postal ballot notices for:

1. Change of the company name
2. Regularization of Mr. Rambhajan Vishwakarma's appointment
3. Regularization and remuneration approval for Mr. Vignesh Laxman Gawde

The e-voting for these resolutions is scheduled to conclude on December 7, 2025.

These changes mark a significant restructuring of Remedium Lifecare's leadership and governance structure, potentially signaling a new direction for the company's operations and strategy.